RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis

Respiratory Medicine

Volumn 122, Issue , 2017, Pages S14-S17

  Distler, Oliver ^a   Pope, Janet ^b   Denton, Chris ^c   Allanore, Yannick ^d   Matucci Cerinic, Marco ^e   de Oliveira Pena, Janethe ^f   Khanna, Dinesh ^g  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d INSTITUT COCHIN   (France)

^e UNIVERSITY OF FLORENCE   (Italy)

^f BAYER CORPORATION   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Fibrosis; Riociguat; Soluble guanylate cyclase; Systemic sclerosis

Indexed keywords

PLACEBO; RIOCIGUAT; CARBON MONOXIDE; ENZYME ACTIVATOR; GUANYLATE CYCLASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DIFFUSE SCLERODERMA; DRUG DOSE TITRATION; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; CLASSIFICATION; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; LUNG DIFFUSION CAPACITY; LUNG EMBOLISM; METABOLISM; PATHOLOGY; PULMONARY HYPERTENSION; QUALITY OF LIFE; SKIN; SKIN DISEASE; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; VITAL CAPACITY;

CARBON MONOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME ACTIVATORS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; PULMONARY DIFFUSING CAPACITY; PULMONARY EMBOLISM; PYRAZOLES; PYRIMIDINES; QUALITY OF LIFE; SCLERODERMA, DIFFUSE; SCLERODERMA, SYSTEMIC; SKIN; SKIN DISEASES; SOLUBLE GUANYLYL CYCLASE; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85008622596     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.09.011     Document Type: Article

References (26)

1. [1] Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT02283762. Accessed July 16, 2015.
2. [2] Ioannidis, J.P., Vlachoyiannopoulos, P.G., Haidich, A.B., et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am. J. Med. 118:1 (2005), 2–10.
3. [3] Clements, P.J., Systemic sclerosis (scleroderma) and related disorders: clinical aspects. Baillières Best. Pract. Res. Clin. Rheumatol. 14:1 (2000), 1–16.
4. [4] Silver, R.M., Clinical aspects of systemic sclerosis (scleroderma). Ann. Rheum. Dis. 50:suppl 4 (1991), 854–861.
5. [5] Denton, C.P., Black, C.M., Pulmonary hypertension in systemic sclerosis. Rheum. Dis. Clin. N. Am. 29:2 (2003), 335–349.
6. [6] Koh, E.T., Lee, P., Gladman, D.D., Abu-Shakara, M., Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br. J. Rheumatol. 35:10 (1996), 989–993.
7. [7] Chatterjee, S., Systemic Scleroderma. 2010, Cleveland Clinic Center for Continuing Education http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/rheumatology/systemic-sclerosis/ (Accessed 18 February 2015).
8. [8] Bakst, R., Merola, J.F., Franks, A.G. Jr., Sanchez, M., Raynaud's phenomenon: pathogenesis and management. J. Am. Acad. Dermatol 59:4 (2008), 633–653.
9. [9] Levien, T.L., Phosphodiesterase inhibitors in Raynaud's phenomenon. Ann. Pharmacother. 40:7–8 (2006), 1388–1393.
10. [10] Pope, J.E., Bellamy, N., Seibold, J.R., et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 44:6 (2001), 1351–1358.
11. [11] Khanna, D., Clements, P.J., Furst, D.E., et al., for the Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 60:4 (2009), 1102–1111.
12. [12] Clements, P.J., Furst, D.E., Wong, W.-K., et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year double-blind, randomized, controlled clinical trial. Arthritis Rheum. 42:6 (1999), 1194–1203.
13. [13] Beyer, C., Distler, J.H.W., Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease. Biochim. Biophys. Acta 1832:7 (2013), 897–904.
14. [14] Van den Hoogen, F., Khanna, D., Fransen, J., et al. 2013 classification criteria for systemic sclerosis. Arthritis Rheum. 65:11 (2013), 2737–2747.
15. [15] Beyer, C., Reich, N., Schindler, S.C., et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann. Rheum. Dis. 71:6 (2012), 1019–1026.
16. [16] Beyer, C., Zenzmaier, C., Palumbo-Zerr, K., et al. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signaling. Ann. Rheum. Dis. 74:7 (2015), 1408–1416 [Epub ahead of print.].
17. [17] Hoeper, M.W., Halank, M., Wilkens, H., et al. Riociguat for interstitial lung disease in pulmonary hypertension: a pilot trial. Eur. Respir. J. 41 (2013), 853–860.
18. [18] Dees, C., Beyer, C., Distler, A., et al. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Ann. Rheum. Dis. 74:8 (2015), 1621–1625 [Epub ahead of print.].
19. [19] Ghofrani, H.A., Galiè, N., Grimminger, F., et al., for the PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 369:4 (2013), 330–340.
20. [20] Maurer, B., Graf, N., Michel, B.A., et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann. Rheum. Dis. 74:6 (2015), 1124–1131.
21. [21] Pope, J., Measures of systemic sclerosis (scleroderma). Health assessment Questionnaire (HAQ) and scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, symptom burden Index (SBI), University of California, Los Angeles, scleroderma clinical trials consortium gastrointestinal scale (UCLA SCTC GIT) 2.0, baseline dyspnea Index (BDI) and transition dyspnea Index (TDI) (Mahler's Index), cambridge pulmonary hypertension outcome review (CAMPHOR), and Raynaud's condition score (RCS). Arthritis Care Res. 63:S11 (2011), S98–S111.
22. [22] Evgenov, O.V., Zou, L., Zhang, M., et al. Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis. BMC Pharmacol., 11(suppl 1), 2011 O9 (abstract).
23. [23] Postlethwaite, A.E., Wong, W.K., Clements, P., et al. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 58:6 (2008), 1810–1822.
24. [24] Merkel, P.A., Silliman, N.P., Clements, P.J., et al., for the Scleroderma Clinical Trials Consortium. Patterns and predictors of change in outcome measures in clinical trials in scleroderma an individual patient meta-analysis of 629 subjects with diffuse scleroderma. Arthritis Rheum. 64:10 (2012), 3420–3429.
25. [25] Amjadi, S., Maranian, P., Furst, D.E., et al., for the Investigators of the D-Penicillamine. Human Recombinant Relaxin, and Oral Bovine Type I Collagen Clinical Trials. Course of modified Rodnan skin score in systemic sclerosis clinical trials: analysis of 3 large multicenter, randomized clinical trials. Arthritis Rheum. 60:8 (2009), 2490–2498.
26. [26] Maurer, B., Graf, N., Michel, B.A., et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann. Rheum. Dis. 74:6 (2015 Jun), 1124–1131.